Article Text

Download PDFPDF
PPIs and anti-TNF in patients with IBD: a forbidden combination?
  1. Judith Wellens1,2,
  2. João Sabino1,2,3,
  3. Séverine Vermeire2,3
  1. 1Gastroenterology and Hepatology, KU Leuven University Hospitals Leuven Gasthuisberg Campus, Leuven, Flanders, Belgium
  2. 2Gastroenterology and Hepatology, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium
  3. 3Department of Chronic Diseases Metabolism and Ageing, KU Leuven University Hospitals Leuven Campus Gasthuisberg, Leuven, Flanders, Belgium
  1. Correspondence to Dr Judith Wellens, Gastroenterology and Hepatology, KU Leuven University Hospitals Leuven Gasthuisberg Campus, Leuven, Flanders, Belgium; Judith.wellens{at}

Statistics from

With great interest, we read the report of Lu et al on the influence of proton pomp inhibitor (PPI) therapy on the outcome of infliximab therapy in inflammatory bowel disease (IBD).1 The authors analysed patient-level data from five randomised controlled trials (RCTs) of patients with IBD treated with infliximab. A total of 1036 patients were enrolled, of whom 147 on PPI therapy. They found that patients on PPI were less likely to achieve remission compared with patients not taking PPIs (OR 0.45, p<0.001) and conclude that PPIs negatively affects outcome in patients with IBD treated with infliximab and PPIs should be prescribed with caution.

We like to congratulate the authors to study the effect of frequently prescribed drugs on the outcome of anti-tumor necrosis factor therapy, since the knowledge on drug–drug interactions is scarce and based on observational research, …

View Full Text


  • Contributors All authors contributed equally to conceptualisation and drafting of the submitted manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.